BioCentury
ARTICLE | Emerging Company Profile

Epitope as prologue

How Hummingbird develops antibodies against epitopes in natural conformation

September 10, 2015 7:00 AM UTC

Most antibody platforms target specific antigens, but offer little control over the exact binding location on the target or how the antibody affects activity. Hummingbird Bioscience Pte. Ltd. has developed a system for pinpointing the binding epitope and selecting antibodies that bind it in its natural configuration.

Hummingbird CEO Piers Ingram told BioCentury most companies begin with screening by peptide immunization against a target antigen to raise specific antibodies, or use phage display...